Zobrazeno 1 - 10
of 457
pro vyhledávání: '"H.-J. Schuurman"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Revue scientifique et technique (International Office of Epizootics). 37(1)
The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation. Allogeneic transplantation is the only successful therapy for several life-threatening diseases, with cell, tissue o
Autor:
H.-J. Schuurman, Julia L. Greenstein
Publikováno v:
European Surgery-Acta Chirurgica Austriaca. 34:58-64
Background: Unlike a solid organ allograft, the rejection of a solid organ porcine xenograft involves almost all branches of the immune system, and prevention or treatment of rejection appears a complicated task. Methods: Part of experience gathered
Autor:
H.-J. Schuurman, K. Mennninger, M. Odeh, W. Slingerland, M. Ossevoort, M. Jonker, J.-C. Hengy, B. Dorobek, J. Vonderscher, J. Ringers
Publikováno v:
Transplant International. 14:320-328
Expanding from the classic use of immunosuppressants in transplantation and rejection, this current overview highlights their new roles in clinical medicine. Immunosuppressants are at the forefront of new treatment modalities. Individual chapters foc
Autor:
J. Oudeman-Gruber, H.-J. Schuurman, Andries C. Bloem, E. J. M. Ahsmann, F. G. C. M. Uytdehaag, Henk M. Lokhorst, M.J.D. van Tol
Publikováno v:
British Journal of Haematology. 89:319-327
The SCID mouse was investigated as a potential animal model for human multiple myeloma (MM). Duplicate samples of bone marrow mononuclear cells (BMMC) and/or peripheral blood mononuclear cells (PBMC) of six MM patients in different clinical phases an
Autor:
H.-J. Schuurman
Publikováno v:
Human & Experimental Toxicology. 14:122-125
Autor:
H. J. Schuurman
Publikováno v:
The Clinical Investigator. 72:715-718
Autor:
J Joergensen, C Steiner, P Herrman, H J Schuurman, M. H. Schreier, S. Wehrli, Walter Schuler, Valérie F. J. Quesniaux
Publikováno v:
Blood. 84:1543-1552
The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL- 2) and interleukin-4 (IL-4). In addition, rapamycin blocks the proliferative response of cell lines to a vari